BioSpace News Archive

NEWPORT BEACH, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its fourth quarter and full year 2019 financial results and provide a business update on Tuesday, February 25, 2020 prior to open of the U.S. financial markets. Management will host a conference call and live webcast to discuss Evolus’ financial results at 8:00 a.m.

CVS Health announced a series of leadership assignments to support the company’s continued focus on innovation and strategic growth.

Twinlab Consolidated Holdings, Inc. (OTCPK:TLCC) (“TCC” or “Twinlab”) a leading nutritional supplement company, today announced that it has entered into an agreement with Bonne Santé Group, Inc. and its subsidiary Bonne Santé Natural Manufacturing, Inc.

CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. Mary Simcox, vice president of translational biology and early development, will give a presentation highlighting the strategy and tactical details for testing CUE-101, the company’s lead biologic drug candidate, in a first-

CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2019 before the U.S. financial markets open on Wednesday, February 26, 2020. Management will host a conference call on February 26, 2020 at 8:30 a.m. ET to di

Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its fourth quarter and full year 2019 financial results after market close on Tuesday, March 3, 2020.

LONDON and REDWOOD CITY, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or the “Company,” today announced that it is distributing approximately 1.2 cents cash per Contingent Value Right (“CVR”), a total of approximately $463,748, related to the $4 million upfront milestone payment from the global license agreement with Oncologie, Inc. (after deduction of costs, charges and expenditures) for the development and commercialization of navicixi

Q4 & FY2019 Earnings Conference Call on March 11th at 4:30 PM EST [12-February-2020] BOTHELL, Wash. , Feb, 12, 2020 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the dates for several ke

SAN DIEGO , Feb. 12, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Joseph Baroldi as Chief Operating Officer. “We are thrilled to welcome Joe to the Avidity team,” said Sarah Boyce , Preside

Correctly and consistently linking patient data across the care continuum remains a significant challenge for U.S. hospitals and health information exchanges (HIEs), according to a new report from eHealth Initiative Foundation and NextGate.